Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth

Hsu, Yu Feng; Wei, Chang-Ching; Shieh, Dar Bin; Chan, Chin-Feng; Chang, Ming Shi

doi:10.1158/1541-7786.mcr-12-0276

Cited by 30 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In keeping with their expression on epithelial cells, receptors for IL-20 subfamily cytokines -such as IL-20RA, IL-20RB and IL-22RA1 -are also readily detected on tumours of epithelial origin. For example, IL-20RA and IL-20RB are expressed on non-small-cell lung cancer, breast cancer, bladder cancer and oral cancer cells [158][159][160][161][162] . IL-22RA1 is detected in colorectal, skin, pancreatic, liver and lung cancers [163][164][165] .…”

Section: Il-20 Subfamily Cytokines In Cancermentioning

confidence: 99%

The IL-20 subfamily of cytokines — from host defence to tissue homeostasis

Rutz¹,

Wang²,

Ouyang³

2014

Nat Rev Immunol

303

326

View full text Add to dashboard Cite

The interleukin-20 (IL-20) subfamily of cytokines comprises IL-19, IL-20, IL-22, IL-24 and IL-26. These cytokines are all members of the larger IL-10 family, but have been grouped together to form the IL-20 subfamily based on their usage of common receptor subunits and similarities in their target-cell profiles and biological functions. Members of the IL-20 subfamily facilitate the communication between leukocytes and epithelial cells, thereby enhancing innate defence mechanisms and tissue repair processes at epithelial surfaces. In this Review, we describe the cellular sources and targets of the IL-20 subfamily cytokines, and we detail how their expression is regulated. Much of our understanding of the unique biology of this group of cytokines is still based on IL-22, which is the most studied member of the IL-20 subfamily. Nevertheless, we attempt a broader discussion of the emerging functions of IL-20 subfamily cytokines in host defence, inflammatory diseases, cancer and metabolism.

show abstract

Section: Il-20 Subfamily Cytokines In Cancermentioning

confidence: 99%

The IL-20 subfamily of cytokines — from host defence to tissue homeostasis

Rutz¹,

Wang²,

Ouyang³

2014

Nat Rev Immunol

303

326

View full text Add to dashboard Cite

show abstract

“…Recent evidence indicates that IL-20 is a therapeutic target in various cancers, including breast cancer, and that an anti- IL-20 monoclonal antibody has therapeutic potential for alleviating inflammation and osteolysis associated with tumor progression [9, 13, 15, 16]. Therefore, we expect that the results of our study will facilitate the development of a new therapeutic strategy for targeting IL-20 expression in various diseases, including cancer.…”

Section: Discussionmentioning

confidence: 78%

“…IL-20 promotes the migration and invasion of bladder cancer cells by activating ERK pathway-mediated MMP-9 protein expression [8]. Furthermore, IL-20 activates STAT3 and ERK signaling in oral cancer cells to increase cell proliferation and colony formation [9]. IL-20 expression is induced by direct binding of the NF-kB p50/p65 heterodimer in human keratinocytes [10].…”

Section: Introductionmentioning

confidence: 99%

A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells

et al. 2017

View full text Add to dashboard Cite

Interleukin-20 (IL-20) is a member of the IL-10 family. IL-20 expression is regulated by a transcription elongation factor, Ell3, in estrogen receptor-positive (ER(+)) breast cancer cells. In this study, we demonstrated that ER(α), GATA3 and FOXA1 form a transcriptional complex with Ell3 to regulate IL-20 expression in ER(+) breast cancer cells. We also determined that GATA3 and FOXA1 share a binding site with ER(α) in the interleukin-20 promoter. Furthermore, we found that FOXA1 represses IL-20 expression, whereas GATA3 and ER(α) activate it. In addition, we demonstrated that Ell3 associates with ER(α) to increase its binding affinity to the IL-20 promoter, which may prevent FOXA1 binding to the same region of this promoter. Our results expand upon the current understanding of the regulatory mechanism of IL-20 in cancer.

show abstract

“…Chronic inflammation is often studied in the context of the mechanisms at work behind the development of cancer. Specifically, pro-inflammatory cytokine interleukin-20 is involved in rheumatoid arthritis, atherosclerosis, osteoporosis, and oral cancer (Hsu et al 2012). The mucosal microenvironment is a specific ecological niche.…”

Section: The Huat Microbiota and Cancersmentioning

confidence: 99%

The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract

et al. 2017

View full text Add to dashboard Cite

Many studies show that the human microbiome plays a critical role in the chronic pathologies of obesity, inflammatory bowel diseases, and diabetes. More recently, the interaction between cancer and the microbiome has been highlighted. Most studies have focused on the gut microbiota because it represents the most extensive bacterial community, and the body of evidence correlating it with gut syndromes is increasing. However, in the strict sense, the gastrointestinal (GI) tract begins in the oral cavity, and special attention should be paid to the specific flora of this cavity. This study reviewed the current knowledge about the various microbial ecosystems of the upper part of the GI tract and discussed their potential link to carcinogenesis. The overall composition of the microbial communities, as well as the presence or absence of "key species", in relation to carcinogenesis is addressed. Alterations in the oral microbiota can potentially be used to predict the risk of cancer. Molecular advances and the further monitoring of the microbiota will increase our understanding of the role of the microbiota in carcinogenesis and open new perspectives for future therapeutic and prophylactic modalities.Key words: upper aerodigestive, microbiome, oral cavity, carcinogenesis.Résumé : Plusieurs études montrent que le microbiome humain joue un rôle essentiel dans les pathologies chroniques que sont l'obésité, les maladies inflammatoires de l'intestin et le diabète. Plus récemment, l'interaction entre le cancer et le microbiome a été soulignée. La plupart des études se sont concentrées sur le microbiote intestinal car il représente la communauté bactérienne la plus étendue, et l'ensemble des preuves le corrélant avec les syndromes de l'intestin est en croissance. Cependant, au sens strict, le tractus gastro-intestinal (GI) commence dans la cavité orale et une attention spéciale devrait être portée à la flore spécifique de cette cavité. Cette étude fait la synthèse des connaissances actuelles relatives à divers écosystèmes microbiens de la partie supérieure du tractus GI et discute de leur lien potentiel à la carcinogenèse. La composition globale des communautés microbiennes, de même que la présence ou l'absence « d'espèces clés » relativement à la carcinogenèse sont soulevées. Des modifications du microbiote oral peuvent potentiellement être utilisées pour prédire les risques de cancer. Les percées moléculaires et la surveillance accrue du microbiote accroitront notre compréhension du rôle du microbiote dans la carcinogenèse et ouvriront de nouvelles perspectives en vue de modalités thérapeutiques et prophylactiques futures. [Traduit par la Rédaction]

show abstract

Anti–IL-20 Monoclonal Antibody Alleviates Inflammation in Oral Cancer and Suppresses Tumor Growth

Cited by 30 publications

References 44 publications

The IL-20 subfamily of cytokines — from host defence to tissue homeostasis

The IL-20 subfamily of cytokines — from host defence to tissue homeostasis

A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells

The oral cavity microbiota: between health, oral disease, and cancers of the aerodigestive tract

Contact Info

Product

Resources

About